Israeli company Nucleai is putting artificial intelligence to work to discover why so many cancer patients don’t respond to immunotherapies, with the help of Swiss drugmaker De
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.